40 results about "RNA polymerase II" patented technology

The invention belongs to the field of fungus species identification and relates to a reference gene for molecular identification of Termitomyces clypeatus and a molecular identification method. Sequences of adopted primers are RPB2B-f: 5'-CCGCAAAGGCTGGTGTATC-3' and RPB2B-r: 5'-TTCGAATGAGTTCAAGTGT-3', and the primers can be used for amplification of large-subunit gene (RPB2) of RNA (ribonucleic acid) polymerase II of the termitomyces clypeatus to obtain a reference detection gene. The termitomyces clypeatus can be quickly and accurately identified according to RPB2 gene DNA (deoxyribonucleic acid) sequence differences. The RPB2 gene overcomes the defect of difficulty in identification of traditional termitomyces clypeatus forms and has the advantages of universality and easiness in amplification and comparison, reliability and accuracy in identification are greatly improved, and a powerful research implement is provided for excavation, protection and utilization of genetic resources of the termitomyces clypeatus.

The invention provides an application of a protein molecular marker in fish germ cell development research. The protein molecule is Anti-RNA polymerase II CTD repeat YSPTSPS (Phospho S5), and the application comprises the step of carrying out immunofluorescence localization analysis on fishes in different development states by adopting the protein molecule as a marker molecule. The immune probe isapplied to fish germ cell development research for the first time, cell facies characteristics of different fish germ cell developments are comprehensively analyzed, an important molecular marker isprovided for judging the development state of the fish germ cells, and a new development function detection strategy is provided for fish genetic breeding.

The invention designs an untranslated region specific artificial micro RNA (miRNA) capable of effectively inhibiting replication of porcine reproductive and respiratory syndrome (PRRS) virus strains, which belongs to the field of researches on gene engineering and biological products. The sequence of the miRNA is represented by one of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4. The invention also discloses the construction of an artificial miRNA expression vector based on RNA polymerase II, design of miRRNAi, synthesis and cloning of double-stranded oligo, detection of expression of miRNA and inhibition effect on replication of different PRRSV strains. Compared with siRNAs for genes of other PRRSVs, the artificial miRNA screened by the invention, according to the conservative sequence of the untranslated region, can inhibit the replication of homologous virus strains and heterologous virus strains and can be used in both the development of anti-PRRSV infection preparations and breeding transgenic pig disease resistance lines.

The invention relates to the field of biotechnology and aims to provide a method for constructing a molecularly marked CSFV (classical swine fever virus) attenuated vaccine. The method comprises following steps: a recombinant plasmid pA-F123 containing genome 5' half-length of a CSFV vaccine strain C and a recombinant plasmid pE-B-Erns containing Erns genes of a BVDV (bovine viral diarrhea virus) strain VEDEVAC are taken as templates, 20bp of homologous fragments are designed at two ends, and by means of a one-step orient cloning kit, a recombinant plasmid pA-B-Erns-F123 is obtained; an F456 fragment containing genome 3' half-length of the CSFV vaccine strain C is cut off from a recombinant plasmid pB-F456 through BamH I and Sal I and cloned into pA-B-Erns-F123 under the action of the same enzyme, and a recombinant plasmid pA-B-Erns-FL is obtained. By virtue of establishment of a reverse genetic manipulation technology, a new way is developed for research of CSFV gene functions and novel vaccines. An exogenous tag is inserted into a viral genome with the reverse genetic manipulation technology for research of virus replication, virus encoded protein functions and anti-virus drug screening, and an RNA (ribonucleic acid) polymerase II system can efficiently and stably save CSFV infectious cDNA (complementary deoxyribonucleic acid ) cloning.

Crystals and structures are provided for an eukaryotic RNA polymerase, and an elongation complex containing a eukaryotic RNA polymerase. The structures and structural coordinates are useful in structural homology deduction, in developing and screening agents that affect the activity of eukaryotic RNA polymerase, and in designing modified forms of eukaryotic RNA polymerase. The structure information may be provided in a computer readable form, e.g. as a database of atomic coordinates, or as a three-dimensional model. The structures are useful, for example, in modeling interactions of the enzyme with DNA, RNA, transcription factors, nucleotides, etc. The structures are also used to identify molecules that bind to or otherwise interact with structural elements in the polymerase.

The invention discloses a gene expression down-regulated vector of cell specificity ndrg2, which comprises an RNAi transgenic vector. A preproinsulin promoter is connected to the RNAi transgenic vector, a miR accessed locus is inserted to the down stream of the preproinsulin promoter, and the miR accessed locus is connected with a miRNA sequence aiming at down-regulated ndrg2 genes. The constructed RNAi transgenic vector adopts the preproinsulin promoter relied by RNA polymerase II to promote the downstream miRNA sequence by specific insulin beta cells of the preproinsulin promoter, and the specific insulin beta cells promote RNA interference aiming at ndrg2 genes to down-regulate the expression thereof; and the vector is used for constructing an animal model and researching the functions of the ndrg2 genes of the insulin beta cells.

The invention provides a use of RNA polymerase II subunit A C-terminal domain phosphatase (CTDP1) or a fragment thereof in preparation of a reagent used for diagnosing Behcet disease (BD). The positive rate of the CTDP1 or the fragment thereof in a BD patient is remarkably higher than that of normal control, a Western blot verification result displays that an anti-CTDP1 antibody can be detected in the serum of the BD patient, which proves that the CTDP1 or the fragment thereof can be used for a detection marker of BD.

The present invention relates to a method for polymerising a complementary RNA strand on a single-stranded polynucleotide template comprising the step of irradiating a composition containing said template and an RNA polymerase of a virus of the Caliciviridae family under RNA polymerisation conditions in the presence or absence of a primer hybridised to the template, with an effective amount of microwave energy. Further subject matter of the invention relates to a method for transferring one or more ribonucleotides to the 3' end of a single-stranded polynucleotide template comprising the step of irradiating a composition containing an RNA polymerase of a virus of the Caliciviridae family in the presence of rATP or rGTP or rUTP or rCTP or a modified or labelled analogue thereof with an effective amount of microwave energy.

The invention discloses an empty carrier for construction of a siRNA expression vector, and a recombinant vector for siRNA and application thereof. The empty carrier, from terminal 5' to terminal 3', comprises: 1) a CMV-derived RNA polymerase II dependent promoter sequence; 2) a pri-MiR21 front fragment sequence as represented by SEQ ID No. 1; 3) the sequence of a cleavage site of restriction endonuclease; 4) a pri-MiR21 rear fragment sequence as represented by SEQ ID No. 2; and 5) a terminator sequence. The recombinant vector for siRNA is obtained by inserting the sequence of siRNA sense sequence-MiR21 ring structure sequence-siRNA antisense sequence to the cleavage site of the restriction endonuclease. According to the invention, since an RNA Pol II promoter is employed, shRNA can be conveniently and effectively connected to the skeleton of pri-MiR21 and be stably expressed through the RNA Pol II promoter, high efficiency expression is realized, and efficiency of knockout and deletion of RNAi is improved.

Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.

The invention discloses a Rhizopus oryzae variant NC-6 for producing L-lactic acid with high yield and high optical purity. The Rhizopus oryzae variant NC-6 was preserved in China General Microbiological Culture Collection Center (CGMCC) on April 20th, 2020, the preservation address is No. 3, No.1 Yard, Beichenxi Road, Chaoyang District, Beijing City, the Rhizopus oryzae variant NC-6 is classifiedand named as Rhizopus oryzae, and the preservation number is CGMCC NO. 19620. The high-yield strain for producing the L-lactic acid with high yield and high optical purity is specifically identifiedas a new Rhizopus oryzae variant by performing morphological analysis, ITS rDNA sequence analysis, whole genome re-sequencing analysis and comparative analysis on sequence similarity Blast of proteincoding genes actin, EF-1 alpha (translation elongation factor 1-alpha) and RPB2 (the largest subunit of the RNA polymerase II). The strain is cultured by shake flask fermentation, and it discovers that the L-lactic acid yield of the strain reaches 78.00 g/L, the sugar conversion rate reaches 73.58%, and the optical purity is 100%; and the strain is cultured by amplification in a 200 L fermentationtank, the L-lactic acid yield of the strain reaches 86.07 g/L, the sugar conversion rate is 83.21%, the optical purity is 100%, and the yield is stable. The strain has wide industrial application prospect.

The present invention provides a method of modulating the expression of a gene containing expanded nucleotide repeats in a cell, comprising: inhibiting the biological activity of SPT4 or SUPT4H; and regulating the formation of R-loops. The inhibition step can effectively reduce the expression of the gene containing the expanded nucleotide repeats and the regulatory step can further enhance the inhibition step. The inhibition step and the regulation step are for the purpose of regulating gene expression by interfering the capacity of RNA polymerase II transcribing over a DNA template with lengthy nucleotide repeats.

The invention relates to the technical field of biology, in particular to application of a CDK7 inhibitor THZ1 in nasopharyngeal carcinoma radiotherapy resistance treatment. According to the invention, the difference of phosphorylation levels of RNA polymerase II C-terminal repetitive domain S5 in nasopharyngeal carcinoma radiotherapy resistance and radiotherapy sensitive cells and after radiotherapy irradiation is carried out on the nasopharyngeal carcinoma radiotherapy resistance and radiotherapy sensitive cells is firstly explored. An inhibitor THZ1 of a CDK7 target spot is adopted to detect nasopharyngeal carcinoma radiotherapy resistance and drug sensitivity of sensitive cells. THZ1 and radiotherapy are combined to act on radiotherapy-resistant cells, and whether THZ1 can increase radiotherapy sensitivity or not is explored. THZ1 is applied to a radiotherapy-resistant mouse model, and the treatment effect of THZ1 on radiotherapy-resistant tumors is explored. The CDK7 inhibitor THZ1 provided by the invention can effectively inhibit the growth of nasopharyngeal carcinoma radiotherapy resistant tumors in an in-vitro level cell experiment and an in-vivo level nude mouse subcutaneous tumor formation experiment. From the cellular level and the animal level, when the THZ1 is combined with the radiotherapy, the radiotherapy sensitivity can be increased, which indicates that the THZ1 is feasible to treat the nasopharyngeal carcinoma radiotherapy resistance.